The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

Immunotherapy, a monumental advancement in antitumor therapy, still yields limited clinical
benefits owing to its unguaranteed efficacy and safety. Therapeutic systems derived from …

While immune checkpoint blockade (ICB) has shown promise for clinical cancer therapy, its
efficacy has only been observed in a limited subset of patients and the underlying …

Large-scale omics profiling has uncovered a vast array of somatic mutations and cancer-
associated proteins, posing substantial challenges for their functional interpretation. Here …

A central goal of cancer genomics is to identify, in each patient, all the cancer-driving
mutations. Among them, point mutations are referred to as cancer-driving nucleotides …

Ovarian clear cell carcinoma (OCCC) is resistant to chemotherapy, with limited treatment
options for advanced and recurrent disease. The prevalence of OCCC differs by region …

Proteolysis-targeting chimera (PROTAC) is a powerful technology that can effectively trigger
the degradation of target proteins. The intricate interplay among various factors leads to a …

Impact of COVID‐19 pandemic on HCV care cascade in Rwanda: Ecological study from July
2019 to June 2021 Page 1 Unraveling bidirectional evolution of unstable mitochondrial DNA …

Background The cellular origin of hypopharyngeal diseases is crucial for further diagnosis
and treatment, and the microenvironment in tissues may also be associated with specific cell …

The proteomic heterogeneity of gastric adenocarcinoma (GC) has been extensively
investigated at the bulk tissue level, which can only provide an average molecular state. In …